Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells

• US 20050180957A1
• Filed: 01/18/2005
• Published: 08/18/2005
• Est. Priority Date: 01/16/2004
• Status: Abandoned Application

• Current Assignee: Novocell, Inc. (Vertex Pharmaceuticals Incorporated)
• Original Assignee: Novocell, Inc. (Vertex Pharmaceuticals Incorporated)
• Inventors: Yu, Xiaojie, Hubbell, Jeffrey, Latta, Paul Presley, Scharp, David William
• Application Number:
  US11/037,727
• Publication Number:
  US 20050180957A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 38/363 Fibrinogen
• CPC Class Codes: A61K 38/37 Factors VIII
• CPC Class Codes: A61K 38/4833 Thrombin (3.4.21.5)
• CPC Class Codes: A61L 24/10 Polypeptides; Proteins A61L24/043 takes precedence
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/507 for artificial blood vessels apparatus for applying cells on a blood vessel prosthesis A61F2/062
• CPC Class Codes: C12N 5/0677 Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

Abstract

The present invention relates to compositions and methods of treating a disease, such as diabetes, by implanting encapsulated biological material with a growth factor and conjugate into a patient in need of treatment. Several methods are presented to accomplish transplanting several different types of biological materials. This invention also provides methods of utilizing these encapsulated biological materials to treat different human and animal diseases or disorders by implanting them into several areas in the body including the subcutaneous site.

Claims

1. A method of stimulating vascularization at a transplant site in an animal comprising:

providing a pharmaceutical composition comprising a fibrinogen, a fibrinolysis inhibitor, an angiogenic growth factor, one or more encapsulated cells, a thrombin and a divalent salt; and

administering the pharmaceutical composition at said transplant site to said animal.

2. The method of claim 1, wherein the angiogenic growth factor is a modified angiogenic growth factor.

3. The method of claim 1, wherein the divalent salt is a calcium salt.

4. The method of claim 1, wherein the administration of the pharmaceutical composition is by injection.

5. The method of claim 1, wherein the angiogenic growth factor is selected from the group consisting of Angiogenin, Angiotropin, Epidermal Growth Factor (EGF), Beta Fibroblast Growth Factor (β

-FGF), Fibroblast Growth Factor-2 (FGF-2), Fibroblast growth factors (FGFs), Heparin-binding EGF-like growth factor, Hepatocyte growth factor (HGF), Insulin-Like Growth Factor I (IGF-I), Interferon-gamma (IFN-gamma), Interferon-g-inducible protein-10 (IP-10), Interleukin-8 (IL-8), Macrophage inflammatory protein-1 (MIP-1), Placental growth factor (PIGF), Platelet Derived Endothelial Cell Growth Factor, Platelet factor-4 (PF-4), Platelet-derived growth factor (PDGF), platelet-derived growth factor-BB (PDGF-BB), Pleiotrophin, Transforming Growth Factor α

(TGF-α

), Transforming Growth Factor β

(TGF-β

), and Vascular Endothelial Growth Factor (VEGF).

6. The method of claim 5, wherein the angiogenic growth factor is VEGF.

7. The method of claim 1, wherein the encapsulated cell is selected from the group consisting of a macroencapsulated cell, a microencapsulated cell and a conformally coated encapsulated cell.

8. The method of claim 1, wherein the encapsulated cell is a cell derived from a stem cell.

9. The method of claim 8, wherein the derived cell is a hormone-producing cell.

10. The method of claim 9, wherein the hormone-producing cell is an insulin-producing cell.

11. The method of claim 1, wherein the encapsulated cell is from the Class Mammalia.

12. The method of claim 11, wherein the encapsulated cell is human.

13. The method of claim 1, further comprising administering, individually or in combination, an immunosuppressant and an anti-inflammatory agent.

14. The method of claim 13, further comprising administering, individually or in combination, the immunosuppressant and anti-inflammatory agent for a period of no more than 6 months from the time of treatment.

15. The method of claim 14, further comprising administering, individually or in combination, the immunosuppressant and anti-inflammatory agent for a period of no more than 1 month from the time of treatment.

16. The method of claim 1, wherein the animal is from the Class Mammalia.

17. The method of claim 16, wherein the animal is Human.

18. The method of claim 1, wherein the pharmaceutical composition additionally comprises Factor XIII.

19. The method of claim 18, wherein a substrate for a transglutaminase activity of Factor XIII is attached to the angiogenic growth factor.

20. A method of preparing a pharmaceutical composition comprising:

(a) preparing a solution comprising a fibrinogen, a fibrinolysis inhibitor, and an angiogenic growth factor to form a fibrinogen/fibrinolysis inhibitor/angiogenic growth factor solution;

(b) adding at least one encapsulated cell to the fibrinogen/fibrinolysis inhibitor/angiogenic growth factor solution; and

(c) adding a thrombin into the encapsulated cell/fibrinogen/fibrinolysis inhibitor/angiogenic growth factor solution of step (b) to produce a pharmaceutical composition comprising a thrombin, at least one encapsulated cell, fibrinogen, fibrinolysis inhibitor, and angiogenic growth factor.

21. A method of stimulating vascularization at a transplant site in an animal comprising administering the pharmaceutical composition prepared by the method of claim 20 to said animal.

22. The method of claim 20, wherein the solution of step (a) additionally comprises Factor XIII.

23. The method of claim 20, wherein the thrombin added in step (c) is in a solution additionally comprising a divalent salt.

24. The method of claim 23, wherein the divalent salt is a calcium salt.

25. A method of preparing a pharmaceutical composition comprising:

(a) preparing a solution comprising a thrombin and an angiogenic growth factor to form a thrombin/angiogenic growth factor solution;

(b) adding at least one encapsulated cell to the thrombin/angiogenic growth factor solution; and

(c) adding a fibrinogen and a fibrinolysis inhibitor into the encapsulated cell/thrombin/angiogenic growth factor solution of step (b) to produce a pharmaceutical composition comprising a fibrinogen, a fibrinolysis inhibitor, at least one encapsulated cell, thrombin and an angiogenic growth factor.

26. A method of stimulating vascularization at a transplant site in an animal comprising administering the pharmaceutical composition prepared by the method of claim 25 to said animal.

27. The method of claim 25, wherein the thrombin added in step (a) is in a solution additionally comprising a divalent salt.

28. The method of claim 27, wherein the divalent salt is a calcium salt.

29. The method of claim 25, wherein the solution of step (c) additionally comprises Factor XIII.

30. A method of stimulating vascularization at a transplant site in an animal comprising:

placing a first solution comprising fibrinogen, fibrinolysis inhibitor, angiogenic growth factor and at least one encapsulated cell into a first barrel of a syringe; and

placing a second solution comprising thrombin into a second barrel of a syringe;

and injecting the first and second solutions into an injection site on said animal.

31. The method of claim 30, wherein the injection site on the animal is subcutaneous, intraperitoneal, intramuscular, intra-omental, or into an organ.

32. The method of claim 31, wherein the injection site on the animal is a subcutaneous site.

33. A method of stimulating vascularization at a transplant site in an animal comprising:

placing a first solution comprising thrombin, angiogenic growth factor and at least one encapsulated cell into a first barrel of a syringe;

placing a second solution comprising fibrinogen and fibrinolysis inhibitor into a second barrel of a syringe; and

injecting the first and second solutions into an injection site on said animal.

34. The method of claim 33, wherein the injection site on the animal is subcutaneous, intraperitoneal, intramuscular, intra-omental, or into an organ.

35. The method of claim 34, wherein the injection site on the animal is a subcutaneous site.

36. A pharmaceutical composition comprising:

a fibrinogen, a fibrinolysis inhibitor, an angiogenic growth factor, one or more encapsulated cells, a thrombin and a divalent salt.

37. The pharmaceutical composition of claim 36, wherein the angiogenic growth factor is selected from the group consisting of Angiogenin, Angiotropin, Epidermal Growth Factor (EGF), Beta Fibroblast Growth Factor (β

-FGF), Fibroblast Growth Factor-2 (FGF-2), Fibroblast growth factors (FGFs), Heparin-binding EGF-like growth factor, Hepatocyte growth factor (HGF), Insulin-Like Growth Factor I (IGF-I), Interferon-gamma (IFN-gamma), Interferon-g-inducible protein-10 (IP-10), Interleukin-8 (IL-8), Macrophage inflammatory protein-1 (MIP-1), Placental growth factor (PIGF), Platelet Derived Endothelial Cell Growth Factor, Platelet factor-4 (PF-4), Platelet-derived growth factor (PDGF), platelet-derived growth factor-BB (PDGF-BB), Pleiotrophin, Transforming Growth Factor α

(TGF-α

), Transforming Growth Factor β

(TGF-β

), and Vascular Endothelial Growth Factor (VEGF).

38. The pharmaceutical composition of claim 37, wherein the angiogenic growth factor is a modified angiogenic growth factor.

39. The pharmaceutical composition of claim 38, wherein the modified angiogenic growth factor is α

-2PI_1-8-VEGF₁₂₁.

40. The pharmaceutical composition of claim 36, wherein the encapsulated cell is selected from the group consisting of a macroencapsulated cell, a microencapsulated cell and a conformally coated encapsulated cell.

41. The method of claim 36, wherein the divalent salt is a calcium salt.

42. The pharmaceutical composition of claim 36, wherein the encapsulated cell is a cell derived from a stem cell.

43. The pharmaceutical composition of claim 42, wherein the derived cell is a hormone-producing cell.

44. The pharmaceutical composition of claim 43, wherein the hormone-producing cell is an insulin-producing cell.

45. The pharmaceutical composition of claim 36, wherein the encapsulated cell is from the Class Mammalia.

46. The pharmaceutical composition of claim 45, wherein the encapsulated cell is human.